I Großimlinghaus1, I Hauth2, P Falkai3, B Janssen4, A Deister5, A Meyer-Lindenberg6, C Roth-Sackenheim7, F Schneider8,9, T Wobrock10,11, R Zeidler12, W Gaebel13. 1. LVR-Institut für Versorgungsforschung, WHO Collaborating Center for Quality Assurance and Empowerment in Mental Health, Medizinische Fakultät, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität, Bergische Landstraße 2, 40629, Düsseldorf, Deutschland. 2. Zentrum für Neurologie, Psychiatrie, Psychotherapie und Psychosomatik, Alexianer St. Joseph Krankenhaus Berlin-Weißensee, Berlin, Deutschland. 3. Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, München, Deutschland. 4. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Medizinische Fakultät, Heinrich-Heine-Universität, Düsseldorf, Deutschland. 5. Zentrum für Psychosoziale Medizin, Klinikum Itzehoe, Itzehoe, Deutschland. 6. Klinik für Psychiatrie und Psychotherapie, Zentralinstitut für Seelische Gesundheit, Universität Heidelberg, Mannheim, Deutschland. 7. Fachärztin für Psychiatrie und Psychotherapie in eigener Praxis, Berufsverband Deutscher Psychiater, Andernach, Deutschland. 8. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, RWTH Aachen University, Aachen, Deutschland. 9. JARA-BRAIN Institute Brain Structure-Function Relationships: Decoding the Human Brain at systemic levels, Forschungszentrum Jülich GmbH and RWTH Aachen University, Jülich, Deutschland. 10. Zentrum für Seelische Gesundheit, Kreiskliniken Darmstadt-Dieburg, Groß-Umstadt, Deutschland. 11. Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Göttingen, Deutschland. 12. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN-Geschäftsstelle), Berlin, Deutschland. 13. LVR-Institut für Versorgungsforschung, WHO Collaborating Center for Quality Assurance and Empowerment in Mental Health, Medizinische Fakultät, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität, Bergische Landstraße 2, 40629, Düsseldorf, Deutschland. Wolfgang.Gaebel@uni-duesseldorf.de.
Abstract
BACKGROUND: In Germany, several quality indicators have been proposed for the measurement of quality of mental healthcare. Some of these quality indicators have been tested in feasibility studies. The German Association for Psychiatry and Psychotherapy (DGPPN) established the "Task Force Quality Indicators (QI)" that, based on previous experience in the development and pilot testing of indicators, considered the further development and practical realization of QI for schizophrenia. AIM: The aim was to select a set of QI for schizophrenia that can also be applied to other diagnoses or used in generic measurements. Another goal was to focus on high feasibility of indicators. METHODS: In a multistage selection process, the DGPPN Task Force selected QI that focus on essential quality aspects from an inventory of 161 existing QI developed by national and international research groups. Indicators were adapted in consultation with the "trialogic forum" of the DGPPN. RESULTS: The DGPPN proposes the following ten indicators for quality measurement in mental healthcare for schizophrenia: QI1 Long-term treatment/Monitoring of side effects, QI2 Seclusion and restraint, QI3 Number of suicides, QI4 Psychoeducational-oriented intervention for significant others, QI5 Timely beginning of outpatient treatment after discharge from inpatient treatment, QI6 Aggression management - inpatient treatment, QI7 Diagnostic procedures/Physical examination, QI8 Antipsychotic polypharmacy, QI9 Rehabilitation/Vocational rehabilitation, QI10 Diagnostic procedures/Psychosocial functioning. DISCUSSION: Most of our proposed QI have to be measured by means of additional data documentation. Based on prior experience in the pilot testing of QI, the DGPPN estimates that the additional efforts in data documentation would be manageable, but have to be refinanced. The indicators will be tested in feasibility studies in different mental healthcare hospitals in Germany.
BACKGROUND: In Germany, several quality indicators have been proposed for the measurement of quality of mental healthcare. Some of these quality indicators have been tested in feasibility studies. The German Association for Psychiatry and Psychotherapy (DGPPN) established the "Task Force Quality Indicators (QI)" that, based on previous experience in the development and pilot testing of indicators, considered the further development and practical realization of QI for schizophrenia. AIM: The aim was to select a set of QI for schizophrenia that can also be applied to other diagnoses or used in generic measurements. Another goal was to focus on high feasibility of indicators. METHODS: In a multistage selection process, the DGPPN Task Force selected QI that focus on essential quality aspects from an inventory of 161 existing QI developed by national and international research groups. Indicators were adapted in consultation with the "trialogic forum" of the DGPPN. RESULTS: The DGPPN proposes the following ten indicators for quality measurement in mental healthcare for schizophrenia: QI1 Long-term treatment/Monitoring of side effects, QI2 Seclusion and restraint, QI3 Number of suicides, QI4 Psychoeducational-oriented intervention for significant others, QI5 Timely beginning of outpatient treatment after discharge from inpatient treatment, QI6 Aggression management - inpatient treatment, QI7 Diagnostic procedures/Physical examination, QI8 Antipsychotic polypharmacy, QI9 Rehabilitation/Vocational rehabilitation, QI10 Diagnostic procedures/Psychosocial functioning. DISCUSSION: Most of our proposed QI have to be measured by means of additional data documentation. Based on prior experience in the pilot testing of QI, the DGPPN estimates that the additional efforts in data documentation would be manageable, but have to be refinanced. The indicators will be tested in feasibility studies in different mental healthcare hospitals in Germany.
Authors: Anne Reiter; Burkhard Fischer; Joachim Kötting; Max Geraedts; Wilfried H Jäckel; Klaus Döbler Journal: Z Arztl Fortbild Qualitatssich Date: 2007
Authors: I Großimlinghaus; P Falkai; W Gaebel; A Hasan; M Jänner; B Janssen; D Reich-Erkelenz; L Grüber; V Böttcher; T Wobrock; J Zielasek Journal: Nervenarzt Date: 2015-11 Impact factor: 1.214
Authors: I Großimlinghaus; P Falkai; W Gaebel; B Janssen; D Reich-Erkelenz; T Wobrock; J Zielasek Journal: Nervenarzt Date: 2013-03 Impact factor: 1.214
Authors: B Janssen; S Weinmann; M Berger; M Härter; T Held; M Leipert; H J Luderer; M Schwarz; T Steinert; W Gaebel Journal: Nervenarzt Date: 2005-03 Impact factor: 1.214